Vigil Neuroscience to Present at Cantor Global Healthcare Conference

Rhea-AI Summary

Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in the Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 9:45 a.m. ET.

Interested parties can register for the live webcast through a provided link. The webcast will also be accessible on Vigil Neuroscience's website in the 'Investors' section under 'Events & Presentations'. An archived version of the webcast will remain available for approximately 90 days after the event.

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET.

To register for the live webcast, please click here. The webcast will also be available on the Company’s website in the “Investors” section under “Events & Presentations.” An archived webcast will be available for approximately 90 days following the event.

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) patients, including some who carry TREM2 and other disease-associated variants.

Internet Posting of Information

Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com

Media Contact:
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com  

FAQ

When is Vigil Neuroscience (VIGL) presenting at the Cantor Global Healthcare Conference?

Vigil Neuroscience (VIGL) is presenting at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET.

How can I watch Vigil Neuroscience's (VIGL) presentation at the Cantor Global Healthcare Conference?

You can watch Vigil Neuroscience's (VIGL) presentation by registering for the live webcast through the provided link or by accessing it on the company's website in the 'Investors' section under 'Events & Presentations'.

How long will the archived webcast of Vigil Neuroscience's (VIGL) presentation be available?

The archived webcast of Vigil Neuroscience's (VIGL) presentation will be available for approximately 90 days following the event.

What is the focus of Vigil Neuroscience's (VIGL) research?

Vigil Neuroscience (VIGL) is focused on harnessing the power of microglia for the treatment of neurodegenerative diseases.